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Analogue peptides with enhanced binding affinity to major histocompatibility class (MHC) I 
molecules are currently being used in cancer patients to elicit stronger T cell responses. 
However, it remains unclear as to how alterations of anchor residues may affect T cell 
receptor (TCR) recognition. We correlate functional, thermodynamic, and structural 
parameters of TCR–peptide–MHC binding and demonstrate the effect of anchor residue 
modifications of the human histocompatibility leukocyte antigens (HLA)–A2 tumor epitope 
NY–ESO-1
 
157–165
 
–SLLMWITQC on TCR recognition. The crystal structure of the wild-type 
peptide complexed with a specific TCR shows that TCR binding centers on two prominent, 
sequential, peptide sidechains, methionine–tryptophan. Cysteine-to-valine substitution at 
peptide position 9, while optimizing peptide binding to the MHC, repositions the peptide 
main chain and generates subtly enhanced interactions between the analogue peptide and 
the TCR. Binding analyses confirm tighter binding of the analogue peptide to HLA–A2 and 
improved soluble TCR binding. Recognition of analogue peptide stimulates faster 
polarization of lytic granules to the immunological synapse, reduces dependence on CD8 
binding, and induces greater numbers of cross-reactive cytotoxic T lymphocyte to 
SLLMWITQC. These results provide important insights into heightened immunogenicity of 
analogue peptides and highlight the importance of incorporating structural data into the 
process of rational optimization of superagonist peptides for clinical trials.
 
A major challenge for the design of cancer
vaccines is that natural tumor antigens elicit
relatively weak T cell responses. One approach
currently being investigated is the optimization
of the MHC class I anchor residues in tumor
epitopes to enhance binding of the peptide to
the MHC class I molecule. Vaccination of
cancer patients with this type of peptide ana-
logue has resulted in larger antigen-specific
CTL expansions than vaccination with wild-
type peptides (1), indicating that the use of
peptide analogs should be considered for fu-
ture clinical trials. However, questions remain
as to how alterations of anchor residues, while
enhancing the peptide–MHC (pMHC) class I
interaction, may affect TCR recognition.
The three-dimensional structures underlying
TCR recognition have important implications
for the design of molecular vaccines (2, 3). Struc-
tural studies have established the molecular char-
acteristics determining peptide binding to MHC
class I molecules (4). By comparison, relatively
few structures of TCR–pMHC complexes
have been solved (5), a particular problem hav-
 
Ji-Li Chen and Guillaume Stewart-Jones contributed equally
to this work.
The online version of this article contains supplemental material.
 
CORRESPONDENCE
Vincenzo Cerundolo: 
vincenzo.cerundolo@
imm.ox.ac.uk 
 
Abbreviations used: CDR, 
complementarity determining 
region; MW, methionine–
tryptophan; pMHC,
peptide–MHC. 
SUPERAGONIST PEPTIDE T CELL VACCINES | Chen et al.
 
1244
 
ing being production of stable, soluble TCRs suitable for
crystallization. One, potentially generic, solution to this
problem is to engineer a novel interchain disulfide bond into
the interface between the TCR constant domains (6), an ap-
proach exploited in the work reported here. Previous studies
have compared the structures of pMHC complexes with
those of altered peptide ligands, for example (7–9). These
comparisons have demonstrated that substitutions of anchor
residues can cause slight structural alterations that may indi-
rectly impact on TCR recognition. Whereas the structural
effects of changing surface exposed peptide residues have
been studied directly in TCR–pMHC complexes (10, 11),
there have been no TCR–pMHC structures determined that
address the effect on TCR recognition of only anchor residue
modifications. However, an example of the impact of changes
at buried MHC class I residues on TCR recognition has been
provided by Luz and colleagues (12).
Several studies have sought to relate the structural char-
acteristics of the TCR–pMHC interface with TCR binding
affinities (13, 14). TCR binding is characterized by low af-
finities (0.1–57 
 
 
 
M) and a degree of cross-reactive recogni-
tion (15, 16). Although peptide analogs bearing substitutions
at anchor residues have been used in several clinical trials (1),
neither the structural effect of these changes, nor how such
features correlate with enhanced immunogenicity in vivo are
well understood. It is important to analyze the molecular ba-
sis for the improved immunological potency of peptide ana-
logs, because such information may provide guidelines for
the rational design of T cell vaccines. Ideally, the properties
of superagonist peptide analogs would blend (a) high affinity
and stability of binding to the MHC class I molecule, (b)
TCR binding properties that elicit potent and effective T
cell expansions, and (c) high levels of TCR cross-reactivity
to the endogenous target epitope on vaccination in vivo.
NY–ESO-1 is one of the most promising tumor-specific
antigens, which was identified by the application of serolog-
ical analysis of recombinant cDNA libraries from human tu-
mors (17, 18). NY–ESO-1 is expressed by a broad range of
tumor types (17). Vaccines designed to boost CTL responses
against NY–ESO-1 epitopes may therefore be useful in the
treatment of many tumors. The A2-restricted NY–ESO-1 T
cell response has been identified using NY–ESO-1–specific
CTL lines derived from melanoma patients and shown to be
specific for the epitope NY–ESO-1
 
157–165
 
 (18). To investi-
gate the structural and kinetic features of TCR recognition
of A2 loaded with the wild-type NY–ESO-1
 
157–165
 
 peptide
(SLLMWITQC; hereafter referred to as “ESO 9C peptide”)
we produced a soluble version of a NY–ESO-1
 
157–165
 
–spe-
 
Table I.
 
 Crystallographic statistics
 
1G4–A2–9C 1G4-A2–9V 1G4
 
Data collection
Space group P2
 
1
 
P2
 
1
 
P2
 
1
 
Unit cell
Dimensions (Å) (a, b, c) 73, 63, 117  73, 63, 117  43, 60, 83
Angles (˚) (
 
 
 
, 
 
 
 
, 
 
 
 
)  90, 105, 90 90, 107, 90 90, 90, 90
Source (
 
 
 
 Å)  ESRF ID14eh2  ESRF ID14eh2 ESRF ID14eh2
Resolution (Å) (highest resolution shell) 20 
 
 
 
 1.9 (1.97 
 
 
 
 1.90)
 
d
 
20 
 
 
 
 1.7 (1.76 
 
 
 
 1.7)
 
d
 
20 
 
 
 
 1.4 (1.46 
 
 
 
 1.4)
 
d
 
Measured reflections 994978 948573 696843
Unique reflections 87826 112638 85029
Completeness (%) 98.5 (96.6)
 
d
 
   89.3 (49.5)
 
d
 
93.0 (62.7)
 
d
 
I/
 
 
 
 (I) 9.8 (1.5)
 
d
 
 19.4 (2.0)
 
d
 
 24.7 (4.3)
 
d
 
R
 
merge
 
 (%)
 
a
 
 6.0  (45)
 
d
 
7.8 (58)
 
d
 
7.8 (32)
 
d
 
Refinement statistics
Resolution range (Å)  20 
 
 
 
 1.9 (1.97 
 
 
 
 1.90)
 
d
 
 20 
 
 
 
 1.7 (1.76 
 
 
 
 1.7)
 
d
 
20 
 
 
 
 1.4 (1.46 
 
 
 
 1.4)
 
d
 
R
 
cryst
b
 
23.0 22.6 24.5
R
 
free
c
 
26.0 25.3 26.5
Number of residues 829 829 444
Number of water molecules 505 512 243
Rms deviation from ideality
Bond lengths (Å) 0.006 0.05 0.005
Bond angles (˚) 1.7 1.3 1.3
Percent Ramachandran plot
(favored, allowed, generous, disallowed)  (90.5, 9.0, 0.4, 0.0)  (89.6, 10.1, 0.3, 0.0)  (85.6, 13.1, 1.3, 0.0)
 
a
 
R
 
merge
 
 
 
   
 
hkl
 
|I 
 
 
 
 
 
 
 
I
 
 
 
|/
 
 
 
hkl
 
I where I is the intensity of unique reflection hkl and 
 
 
 
I
 
 
 
 is the average over symmetry-related observation of unique reflection hkl.
 
b
 
R
 
cryst
 
 
 
   
 
|F
 
obs
 
 
 
 
 
 F
 
calc
 
|/
 
 
 
F
 
obs
 
 where F
 
obs
 
 and F
 
calc
 
 are the observed and calculated structure factors, respectively.
 
c
 
R
 
free
 
 is calculated as for R
 
cryst 
 
but using 4.4% of reflections sequestered before refinement.
 
d
 
Numbers in parentheses correspond to the outermost shell of data. 
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cific TCR. Our initial analysis revealed that TCR interac-
tions with this native epitope are dominated by two highly
exposed residues, methionine and tryptophan, whose side
chains protrude from the central part of the peptide (at posi-
tions 4 and 5). The presence of this prominent hydrophobic
feature suggests that for this system TCR binding in general
will focus on the central region of the peptide and be rela-
tively tolerant of changes in the pMHC surface near the
peptide carboxyl terminus. To test this hypothesis and its
implications for the immunogenic characteristics of the sys-
tem, we performed a series of studies to provide structural,
solution binding, in vitro functional and in vivo immuno-
genic data. Because we had previously demonstrated that
substitution of the cysteine to valine at position 165 (19) en-
hances the ability of the epitope to be recognized in vitro by
NY–ESO-1
 
157–165
 
–specific CTL, we focused on this peptide
analogue (SLLMWITQV; hereafter referred to as “ESO 9V
peptide”). Our results provide insights into the mechanisms
controlling the enhanced immunogenicity of superagonist
peptides by demonstrating a correlation between the stability
of the peptide–MHC–TCR complex, its ability to stimulate
a faster formation of conjugates, resulting in polarization of
lytic granules, killing of target cells, and in vivo proliferation.
 
RESULTS
Structure of the TCR and ESO 9C–A2 complex
 
Structural studies were performed using soluble, purified
TCR (6) from the NY–ESO-1
 
157–165
 
–specific 1G4 CTL
clone (hereafter 1G4 TCR). The 1G4 TCR–A2–ESO 9C
complex crystal diffracted to 1.9 Å resolution and contained
one complex per asymmetric unit (Table I). A 1.4-Å resolu-
tion crystal structure was also determined for the unliganded
1G4 TCR. In the complex structure the orthogonal binding
orientation of the 1G4 TCR with respect to the long axis of
the ESO 9C peptide (69
 
 
 
) lies at one extreme of the range
observed, to date, for TCR–pMHC class I interactions and
is very similar to the orientation observed for the JM22
TCR–A2–influenza matrix peptide complex (20). These
two structures, plus that recently reported for the TCR
AHIII–A2–p1049 complex (21), establish that there is signif-
icant overlap between the binding orientations for class II–
and class I–restricted TCR recognition.
The 1G4–A2–ESO 9C complex displays a prominent
methionine–tryptophan (MW) “peg” in the central P4/P5
portion of the peptide, which forms a large protrusion from
the surface of the pMHC (Fig. 1, A and B). The 1G4 TCR
envelops this protrusion between its complementarity deter-
mining region (CDR) loops, making contacts via the
CDR3
 
 
 
,CDR3
 
 
 
 and CDR1
 
 
 
 loop residues. In previous
pMHC–TCR complex structures, a single upward pointing
residue from the peptide has often formed a peg about
which the TCR CDR loop residues cluster making contacts
conferring specificity and affinity (5, 22, 23). In this case, the
peg is composed of a double side chain motif. This bulky
and hydrophobic structure provides the majority of interac-
tions between the epitope and the 1G4 TCR. More gener-
ally, given its central position within the TCR recognition
surface, it seems probable that the MW peg constitutes the
dominant antigenic feature of this peptide (Fig. 1 A).
The total solvent-accessible surface area buried at the
1G4 TCR–A2–ESO 9C interface is 
 
 
 
1,440 Å
 
2
 
 with the
TCR contribution being split relatively equally between 
 
 
 
and 
 
 
 
 chains, 46% and 54%, respectively. Of this total 730
Å
 
2
 
 (
 
 
 
50%) results from TCR–peptide interactions with 49%
of the buried surface area between the ESO 9C peptide and
the 1G4 TCR accounted for solely by interactions involving
the MW side chains (360 Å
 
2
 
). Analyses of the shape comple-
mentarity at the interface between the 1G4 TCR and (a) the
pMHC (S
 
c
 
 
 
 
 
 0.71), (b) the entire ESO 9C peptide (S
 
c
 
 
 
 
 
0.83), and (c) specifically the MW side chains (S
 
c
 
 
 
 
 
 0.87)
demonstrate that there is a very high degree of shape com-
plementarity to the epitope, in particular to the MW peg.
Rudolph and colleagues calculated S
 
c
 
 values ranging from
0.41 to 0.66 (with most clustered between 0.61–0.66) for
the nine TCR–pMHC complex structures available in 2002
(5). Where the resolution of the x-ray diffraction data is suf-
ficient for conserved water molecules to be included in the
structure, these are frequently found to be integral to
the pMHC–TCR interactions (12, 20, 24). For example, in
the JM22–flu matrix
 
58–66
 
–HLA–A2 complex S
 
c
 
 equals 0.73,
with interfacial waters included in the calculation, and 0.64
without (20). The 1G4 TCR–A2–ESO 9C interface is notable
in that it achieves high S
 
c
 
 values without any contribution
from interfacial water, because the interface between the MW
side chains and the TCR CDR3
 
 
 
CDR3
 
 
 
 and CDR1
 
 
 
 loops
contains no trapped water molecules. The core of the 1G4
TCR–A2–ESO 9C interface is stabilized by hydrophobic
and ring-stacking interactions, consistent with the hydro-
phobic and aromatic nature of the peptide M and W side
chains (Fig. 1, C and D). Instead, water molecules cluster at
the periphery of this pMHC–TCR interface, forming a belt
associated with the peptide, TCR and A2, which may con-
tribute to the thermodynamic properties of 1G4 TCR rec-
ognition (unpublished data).
Previous studies that have compared TCR structures in
unbound and complexed states (25–29) report remarkably
large (up to 15 Å) conformational changes in the CDR3 
 
 
 
and   loops. Although the 1G4 TCR uses a substantial cav-
ity to accommodate the MW peg between its CDR1 ,
CDR3 , and CDR3  loops (Fig. 1 C), this cavity is pre-
formed (Fig. 1 E). In contrast with the mechanisms of in-
duced TCR fit reported for other pMHC–TCR complexes,
a well optimized binding surface is achieved by relatively
small structural changes. Comparison of the unliganded and
liganded 1G4 TCR structures reveals only relatively minor
main chain shifts in all the CDR  loops (for example,  1.6
Å for V96  at the tip of the CDR3 ; Fig. 1, C and E). The
largest main chain shifts (up to 4.2 Å) in the V  domain also
occur at the tip of the CDR3 loop resulting from a change
in the main chain conformation of residues 95–99. OnlySUPERAGONIST PEPTIDE T CELL VACCINES | Chen et al. 1246
subtle adjustments in preexisting (unliganded) side chain
conformations appear to be required to optimize the interac-
tion of Y100  with the peptide at M4 and ring-stacking in-
teractions between Y31  and the W5 side chain. However,
these TCR residues show a considerable reduction in flexi-
bility on engagement with the MW peg (average crystallo-
graphic temperature factors for the side chain atoms of Y31 
are 36 Å2 unliganded and 23 Å2 liganded, and for Y100  the
values are 50 Å2 unliganded and 22 Å2 liganded).
Comparison of the 1G4 TCR–ESO 9C–A2 and 1G4 TCR–ESO 
9V–A2 complexes
Because the 1G4 TCR recognition appears to be so focused
on the central region of the peptide, we wished to assess
Figure 1. Structure of 1G4 TCR bound to A2–NY–ESO-1 complexes. 
(A) Diagram highlighting the CDR loops of the 1G4 TCR complexed to the 
A2–ESO 9C. The CDR loops are colored as follows: V CDR1, blue; V CDR2, 
cyan; V CDR3, green; V CDR1, red; V CDR2, orange; and V CDR3, magenta. 
The peptide (yellow) projects a bulky methionine-tryptophan peg, which is 
embedded deep within the TCR CDR loops. (B) Simulated annealing omit 
electron density map yellow chicken wire showing the M4W5 residues 
bound by the 1G4 TCR. TCR contact residues are colored according to CDR 
color as in panel A. Hydrogen bonds between the CDR3  and the M4W5 
residues are shown in black. The map is contoured at 3 . (C) Illustration of 
the complexed TCR colored according to panel A, and showing the close 
interaction of the hydrophobic peptide MW peg (yellow) with the TCR 
Y31  and Y100  side chains. (D) Schematic diagram showing the interac-
tions between the M4W5 peg residues and the surrounding 1G4 TCR resi-
dues. TCR contact residues with a minimum interatomic distance of  3.8 Å 
are shown in green, whereas other residues surrounding the M4W5 peg are 
shown in blue. The individual distances between the TCR and the M4W5 
peg are shown as dashed lines (distances  3.4 Å are shown in pink; dis-
tances between 3.4 Å and 3.8 Å are in light blue; hydrogen bonds are 
shown with distances in black). (E) View of the TCR antigen combining 
surface from the perspective of pMHC with CDR loop surfaces colored 
according to panel A. The figure shows the structure of the uncomplexed 
TCR, highlighting the Y30  and Y100  side chains. (F)  1 2 helix superim-
position of the ESO 9C (green peptide and dark-green TCR) and ESO 9V 
(pink peptide and red TCR) TCR–peptide structures showing the subtle 
differences the anchor residue modification propagates throughout the 
complex interface. Notably, the COOH-terminal half of the ESO 9C peptide 
is 0.6 Å further out of the HLA–A2 groove than the 9V peptide and the tip 
of the CDR3  loop is lower compared with the TCR–A2–ESO 9V complex.JEM VOL. 201, April 18, 2005 1247
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whether substitutions of the carboxyl-terminal residue of the
NY–ESO-1 peptide could alter the peptide structure and af-
finity of interaction with the 1G4 TCR. Because we have
previously shown that substitution of cysteine to valine at
position 165 of the NY–ESO-1157–165 epitope enhanced its
ability to sensitize target cells for killing by the 1G4 CTL
clone (19), we decided to focus further structural studies on
the 9V NY–ESO-1 peptide analogue (ESO 9V).
The crystal structure of the 1G4 TCR–A2–ESO 9V
complex was determined at 1.7 Å resolution from crystals of
the same space group and essentially identical unit cell di-
mensions to those used for the 1G4–A2–ESO 9C structure.
To a first approximation the two complex structures are very
similar. Structural comparison reveals that substitution of the
cysteine to valine causes little difference in the general orien-
tation of the side chain within the F pocket of the A2 pep-
tide binding groove. Changes in the positions of the A2 side
chains constituting the F pocket are also minimal. However,
the relatively high resolution of both the 1G4–A2–ESO 9C
and 1G4–A2–ESO 9V crystal structures permits a detailed
analysis (Fig. 1 F). It is evident that the ESO 9V side chain is
buried deeper into the F-pocket and occupies a slightly
larger volume than the cysteine side chain. Both the shape
complementarity and the buried surface within the F-pocket
is greater for ESO 9V compared with ESO 9C (side chain
surface areas: ESO 9V   191 Å2, ESO 9C   162 Å2 and
shape complementarities: ESO 9V   0.81, ESO 9C  0.72).
These changes are sufficient to enhance significantly the van
der Waal’s contacts between the altered peptide ligand and
A2, in line with this MHC class I molecule’s reported pref-
erence for valine as COOH-terminal anchor residue (30).
The changes in the position of the COOH-terminal an-
chor residue, resulting from the C9V substitution, propagate
through the peptide main chain resulting in the P6–P8 re-
gion being positioned slightly deeper (0.3 Å) within the A2
peptide binding groove. Although the P6–P8 region of the
peptide has fewer contacts with the 1G4 TCR than the MW
peg at P4 and P5, the structural difference in the peptide is
clearly transmitted to the TCR (Fig. 1 F). The angle of en-
gagement made by the 1G4 TCR differs between the pep-
tide complexes by some 0.9 . This is essentially a change in
the TCR’s tilt, relative to an axis drawn perpendicular to the
pMHC binding surface, in response to the lower position of
the main chain COOH-terminal half of the ESO 9V pep-
tide. Numerous small changes are discernible at the complex
Figure 2. Binding measurements of peptide to A2 molecules and 
pMHC complex to TCR. (A) HLA A2–peptide complexes were precipitated 
from T2 lysate pulsed either with ESO 9C or ESO 9V peptide at concentra-
tions shown. HLA-A2 molecules from T2 cells pulsed with either 3  M flu 
matrix58–66 peptide or in the absence of peptide (open bar) were used as 
positive and negative controls. ESO 9C, ESO 9V, and flu matrix58–66 pep-
tides were treated with 20 mM TCEP at room temperature for 1 h before 
being added to the T2 cell lysate at the final concentration of 200  M. 
(B) T2 cells were stained with the A2–ESO 9C-specific Fab antibody 3M4E5. 
T2 cells were pulsed with either ESO 9C (left column) or ESO 9V (right col-
umn) at concentrations shown. Negative control staining with flu matrix 
peptide is shown in the top panel. Mean channel fluorescence is shown in 
each panel. (C) Affinity measurements for TCR binding to A2 complexed 
with ESO 9C and ESO 9V are shown in panels a and b and c and d, respec-
tively. Panels a and c show measurements at equilibrium, whereas panels b 
and d show kinetic measurements. Panels a and c show 10 serial dilutions in 
duplicates of 1G4 NY–ESO-1–TCR (analyte), starting from a concentration 
of 240  M. Panels b and d show six serial dilutions in duplicates of 1G4 
NY–ESO-1–TCR, starting from a concentration of 24  M.SUPERAGONIST PEPTIDE T CELL VACCINES | Chen et al. 1248
interface. These changes are focused on residue Q155 of the
A2  2 helix. For the A2–ESO 9V complex the Q155 side
chain is well ordered and makes hydrogen bonds to the O 
atoms of S52 and S53 side chains. In contrast, for the A2–
ESO 9C complex the Q155 side chain is relatively disor-
dered and appears to be sampling an additional conforma-
tion, forming a hydrogen bond to T95  on the CDR3 
loop of the 1G4 TCR. The change in TCR tilt of the A2–
ESO 9V complex precludes the latter option and the
CDR3  loop adopts a less well ordered structure. The aver-
age B-factor for residues in the tip of CDR3  loop (all at-
oms in Ser96   and Gly97  ) are 33.93 and 42.46 for the
A2–ESO 9C and A2–ESO 9V complexes, respectively.
Analysis of the shape complementarity between the 1G4
TCR and the pMHCs suggests a slightly better overall fit is
achieved with A2 /ESO 9V (Sc   0.73) compared with A2–
ESO 9C (Sc   0.71). The significance of this difference in Sc
is discussed in Materials and methods. The difference in-
cludes tighter interactions between TCR and variant peptide
(ESO 9V peptide Sc   0.85; ESO 9C peptide Sc   0.83).
Enhanced binding affinity of ESO 9V peptide for A2 
molecules and slower 1G4 TCR dissociation rate from 
the ESO 9V–A2 complex
Our comparison of the ESO 9C- and ESO 9V-based com-
plex structures revealed the substitution of cysteine at posi-
tion 9 by valine provides an improved fit to the A2 F pocket,
a result that might be expected on the basis of established an-
chor preferences. However, this substitution, at a position
buried within the binding groove, was also revealed to trig-
ger subtle, but significant, changes at the TCR–pMHC in-
terface. To correlate these structural features of the TCR–
pMHC complexes with kinetics of binding, we assessed the
affinity of binding of the ESO 9V and ESO 9C peptides to
A2 molecules, and the affinity of 1G4 TCR binding to A2
molecules loaded with either the ESO 9V peptide or the
wild-type ESO 9C peptide. Binding of ESO 9V peptide to
A2 molecules was compared with that of ESO 9C by mea-
suring peptide binding to metabolically labeled A2 molecules
in T2 cells (31). Measurement of the optical density of meta-
bolically labeled A2 SDS gel bands showed that ESO 9V
peptide can stabilize a higher proportion of A2 molecules
than the ESO 9C peptide (Fig. 2 A).
To confirm these results, experiments were performed
using the 3M4E5 Fab antibody specific to NY–ESO-1157–165–
A2 complexes (32). Initial Biacore measurements dem-
onstrated that the 3M4E5 Fab antibody recognizes A2 mole-
cules loaded with either ESO 9V or ESO 9C peptide with a
similar affinity of  60 nM (unpublished data). FACS stain-
ing with the 3M4E5 antibody of T2 cells pulsed with differ-
ent concentrations of ESO 9V and ESO 9C peptides con-
firmed that ESO 9V peptide binds to A2 molecules with
greater efficiency than the ESO 9C peptide (Fig. 2 B).
Surface plasmon resonance affinity measurements were
performed using the soluble form of 1G4 TCR in order to
compare the affinity of binding of a NY–ESO-1157–165–spe-
cific TCR to A2 molecules loaded with either the wild-type
ESO 9C peptide or the ESO 9V analogue. The experiments
demonstrated a higher affinity of binding for the 1G4 TCR
to the A2–ESO 9V complex than to the A2–ESO 9C com-
plex (Fig. 2 C). Analysis of the binding curves of conforma-
tion-specific anti-A2–peptide and anti- 2M antibodies con-
Figure 3. 1G4 CTL–T2 conjugates formation is very efficient when 
targets are loaded with ESO 9V peptide. The panel shows a series of 
selected images taken from the live-cell videos in Videos 1 and 2 (available 
at http://www.jem.org/cgi/content/full/jem.20042323/DC1). CTLs loaded 
with lysotracker green were added to the adherent T2 target cells pulsed 
with 1  M ESO 9C (A–E; and Video 1) or pulsed with 1  M ESO 9V (F–L; 
and Video 2). The images selected from the Video 1 correspond to time 0 
(A) indicating the first contact of a CTL with T2 pulsed with ESO 9C, 5 min 
(B), 12 min, and 20 s (C), 15 min and 20 s (D), 22 min and 40 s (E) and the 
ones taken from Video 2 are, respectively: time 0 (F), 1 min and 40 s (G), 
5 min and 40 s (H), 6 min and 20 s (I), and 9 min and 40 s (L). The Normaski 
differential interference contrast image (blue) and 1  M of green confocal 
image have been super-imposed at each time point. White, red, black, and 
light blue arrows indicate the CTLs described in the results. Bars, 10  m.JEM VOL. 201, April 18, 2005 1249
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firmed that equivalent amounts of correctly refolded A2–
peptide complexes were immobilized to the Biacore chips
(Fig. S1, A and B). Good agreement was observed between
the affinities determined kinetically (the ratio of Koff to Kon)
and those determined by equilibrium measurements. The
equilibrium binding constants (Kd) at 25 C for the soluble
1G4 TCR binding to A2 loaded with the ESO 9V or ESO
9C peptide were determined to be 5 and 13.3  M, respec-
tively (Fig. 2 C). Kinetic measurements demonstrated that
the higher affinity of binding was predominantly due to a
slower off rate for the 1G4 TCR when bound to the A2–
ESO 9V complex compared with the A2–ESO 9C complex.
The slower off-rate is in line with the structural data, which
indicate that more pMHC–TCR contacts form at the ESO
9V interface than at the ESO 9C interface.
ESO 9V induces polarization of CTL granules more 
efficiently than the wild type
To assess the functional consequences of the differences in
pMHC and TCR–pMHC binding affinities, we analyzed
the rate of polarization of cytotoxic T cell granules on stim-
ulation of a NY–ESO-1157–165–specific CTL clone with tar-
get cells pulsed with either the ESO 9C or the ESO 9V pep-
tides. These experiments were performed with the same
1G4 CTL clone for which the structural and kinetic studies
had been derived.
When T2 cells are pulsed with 1  M ESO 9C peptide
(Video S1 and Fig. 3, A–E), lytic granule polarization is
slow. Fig. 3, A–E, shows two CTLs from contact to polar-
ization. In one case (white arrow) granule polarization from
the periphery (Fig. 3 B) to the synapse (Fig. 3 E) occurs
within 17 min after the initial contact. In the other example
(red arrow), the CTL first crawls under one target (Fig. 3, A
and B) before contacting a new target (Fig. 3 C) without po-
larization of the lytic granules toward either target in  22
min. In contrast, granule polarization is rapid when T2 tar-
gets are pulsed with 1  M ESO 9V peptide (Video 2 and
Fig. 3, F–L). For one CTL, from the first encounter (Fig. 3
F, green arrowhead) to granule polarization (Fig. 3 L) the
elapsed time is 4 min. Other CTLs in the field being filmed
(Fig. 3 L, black arrowheads) had already polarized their gran-
ules toward targets by the time images were captured.
CTL and target cells were mixed with different concen-
trations of the two peptides, incubated at 37 C for 30 min
and fixed in order to provide quantitative data with a large
number of conjugates. Lytic granules were labeled with anti-
bodies against cathepsin D (Fig. 4 A, a–c, green) and the p58
Golgi protein (Fig. 4 A, a–c, red). Both the Golgi apparatus
and granules polarize upon CTL recognition of target (33),
and the degree of polarization in CTL conjugated to targets
were counted according to whether granules and Golgi pro-
teins were located (a) at the rear of the CTL (Fig. 4 A, a, un-
Figure 4. ESO 9V is very efficient in inducing polarization of CTL 
granules at the immunological synapse. (A) The confocal images show 
1G4 CTLs conjugated with T2 pulsed with 1  M ESO 9V. Lytic granules 
stained with anti-cathepsin D (green) and anti-p58 cis Golgi protein (red). 
Upon target cell recognition both Golgi and lytic granules move from the 
rear of the cell (a), around the nucleus (b), and polarize at the immunologi-
cal synapse (c). (B and C) Quantitative analysis of granule polarization in 
1G4 CTL clone recognizing targets pulsed with ESO 9C (B) or ESO 9V pep-
tides (C). Cell conjugates with granules at the rear (white bar), granules 
moving laterally toward the synapse (gray bar) and granules at the synapse 
(black bar) as illustrated in A were counted using a fluorescence microscope.SUPERAGONIST PEPTIDE T CELL VACCINES | Chen et al. 1250
polarized); (b) at the side of the CTL (Fig. 4 A, b, polariz-
ing); or (c) polarized at the immunological synapse (Fig. 4 A
c). When T2 cells were pulsed with the ESO 9C peptide
polarization was poor (Fig. 4 B) and 1  M of peptide was
required to see 30% of conjugates with tightly polarized
granules at the synapse. By comparison, for ESO 9V granule
polarization is much more efficient and only 0.01  M ESO
9V peptide is required to see 30% of polarized CTL (Fig. 4
C). The higher percentage of target cell killing (19) and se-
cretion of lymphokines (Fig. 5) may therefore reflect the
shorter times required for CTL to recognize and destroy in-
dividual targets.
Differential role of CD8 binding in CTL recognition of 
A2–ESO 9V and A2–ESO 9C
We sought to assess whether the CD8 requirement of the
1G4 NY–ESO-1157–165–specific CTL clone differed for the
recognition of wild-type ESO 9C or ESO 9V analogue pep-
tides (Fig. 5). We show that recognition of the ESO 9V pep-
tide is less CD8 dependent than recognition of the ESO 9C
peptide, because CTL recognition of ESO 9C was signifi-
cantly more efficient in the presence of A2 molecules bear-
ing a CD8 binding site. These results also confirm that the
1G4 CTL clone is up to 100 times more sensitive to the
ESO 9V peptide compared with the ESO 9C peptide.
Enhanced in vivo immunogenicity of ESO 9V peptide analogs
We assessed whether the ESO 9V peptide is capable of ex-
panding in A2 transgenic mice greater numbers of NY–
ESO-1157–165–specific CTL that are cross reactive to the na-
tive epitope. The results show that recombinant vaccines
encoding the ESO 9V peptide are capable of inducing stron-
ger NY–ESO-1157–165 responses than vaccines encoding the
wild-type ESO 9C peptide, both in terms of percentages of
responding mice and frequency of the T cell response in-
duced (Fig. 6 A). Furthermore, ESO 9V–primed mice were
capable of recognizing the wild-type ESO 9C peptide, as de-
fined by ex vivo tetramer staining with A2Kb tetramers
loaded with the ESO 9C peptide (Fig. 6 B). The proportion
of NY–ESO-1157–165–specific CTL, stained by A2Kb tetra-
mers loaded with either the ESO 9C or the ESO 9V peptide
was very similar. Consistent with these findings, in vitro kill-
ing assays showed that NY–ESO-1157–165–specific CTL, gen-
erated from ESO 9V–immunized mice, were capable of lys-
ing target cells loaded with wild-type ESO 9C peptide, as
well as target cells loaded with the ESO 9V analogue (Fig. 6
C). IFN-  ELISPOT assay was used to assess further cross
reactivity and the function of these CTL. CTL generated
from animals immunized with the ESO 9V sequence were
capable of producing IFN-  in response to ESO 9C peptide.
As expected, responses were enhanced in the presence of the
reducing agent TCEP, which prevents cysteinylation and
dimerization of ESO 9C peptide (unpublished data (19, 34).
Finally, a larger proportion of ESO 9V–primed T cells was
capable of secreting IFN- , when stimulated by target cells
pulsed with ESO 9C peptide, than ESO 9C primed T cells
(Fig. 6 D). Enhanced IFN-  response by T cells from ESO
9V–primed mice was not due to the higher numbers of ESO
9V–primed T cells, because the numbers of splenocytes from
ESO 9V and ESO 9C primed mice added to the ELISPOT
plates were normalized for the percentage of ESO 9C tet-
ramer positive T cells.
DISCUSSION
Previous studies (35) have raised the issue that changes in
peptide anchor residues can directly affect TCR recognition,
as well as pMHC stability. Such effects have important im-
plications for T cell cancer vaccines. A2–ESO 9C represents
a clinically relevant system in which we can assess the factors
that will need to be considered when engineering vaccine
epitopes. Because it is known that cysteinylation may reduce
antigenicity of synthetic peptides binding to MHC class I
molecules (34), we sought to study whether modification of
cysteine 165 in the NY–ESO-1157-165 epitope would increase
its immunogenicity. Our results demonstrate that modifica-
tion of cysteine to valine at position 165 of NY–ESO-1157–165
both augments epitope binding to MHC and heightens
TCR affinity. These two properties act in concert to gener-
Figure 5. Role of CD8 in the recognition of the ESO 9V and ESO 
9C peptides. CIR B cells transfected with either wild-type A2 or A2 
DT227/8KA were pulsed with either ESO 9V or ESO 9C peptides. Superna-
tant was assayed for MIP-1  (top) or IFN-  (bottom) by ELISA. Standard 
deviation from the mean of two duplicate assays is shown. Diamonds in-
dicate target cells pulsed with ESO 9V peptide. Circles indicate target cells 
pulsed with ESO 9C peptide.JEM VOL. 201, April 18, 2005 1251
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ate stronger T cell cytolysis and activation, without compro-
mising cross-reactivity with the wild-type peptide. Valine,
while optimizing the anchoring of the peptide in the A2 F
pocket, does not alter the orientation and height of the pep-
tide’s prominent methionine–tryptophan TCR binding mo-
tif. However, subtle repositioning of the peptide main chain
introduces some small but significant changes at the pMHC–
TCR interface which appear sufficient to generate a lower
TCR Koff rate.
To elicit effective antitumor responses, it is important to
develop strategies capable of reversing T cell tolerance to tu-
mor antigens and jump starting the immune response to ex-
pand rapidly greater numbers of tumor-specific CTL. Al-
though previous papers have correlated higher affinity of
peptide binding to MHC class I molecules and TCR with
increased immunogenicity (36–40), none of the previous
studies have compared functional data to structural and ki-
netic analyses.
The use of a Fab antibody specific to the A2/NY–ESO-
1157–165 peptide complex (32) permits comparison of the effi-
ciency of ESO 9C and ESO 9V binding to surface expressed
A2 molecules (Fig. 2 B). The results of these experiments are
consistent with  100-fold difference in binding affinity to A2
molecules between the ESO 9C and ESO 9V peptides. They
also show that, within the range of peptide concentrations
used for the analysis of granule polarization (Figs. 3 and 4) and
cytokine secretion (Fig. 5), cells pulsed with ESO 9V peptide
present to the 1G4 CTL clone approximately three- to five-
fold more peptide than cells pulsed with the ESO 9C peptide.
These results suggest that the enhanced effector functions of
Figure 6. Enhanced in vivo immunogenicity of ESO 9V vaccines. 
(A) A2Kb transgenic mice were immunized with plasmid DNA followed by 
recombinant vaccinia virus encoding either ESO 9C or ESO 9V peptides. 
Splenocytes from immunized mice were stained ex vivo 1 wk after vaccinia 
injection with A2Kb tetramers loaded with ESO 9C peptide (57). Results 
from four separate experiments were combined, each experiment includes 
five to eight mice (P   0.0001). (B and C) Splenocytes from ESO 9V–
immunized mice are capable of recognizing ESO 9C peptide. B shows that 
PBL from mice immunized with ESO 9V vaccines were ex vivo stained with 
A2Kb tetramers containing either ESO 9C (top row) or ESO 9V (bottom row) 
peptides. Percentage of tetramer  of CD8  cells is shown in each panel. 
C shows lysis of target cells (Jurkat cells transfected with A2Kb cDNA) 
pulsed with either ESO 9V or ESO 9C peptide. Target cells pulsed with the 
irrelevant peptide flu matrix58–66 (Flu) were used as negative controls. To 
ensure optimal presentation of the ESO 9C peptide, lysis of target cells 
pulsed with ESO 9C peptide was compared in the presence or absence of 
the reducing agent TCEP. In agreement with our previous results (19), ESO 
9C pulsed target cells were killed more efficiently in the presence of the 
reducing agent TCEP (ESO 9C TCEP) than in the absence of TCEP (ESO 9C). 
(D) Enhanced IFN-  response by T cells from ESO 9V–primed mice. Spleno-
cytes from either ESO 9V– or ESO 9C–immunized mice were tested for 
their ability to recognize target cells pulsed with ESO 9C peptide. Duplicate 
samples were used. Peptide concentrations and numbers of tetramer pos-
itive T cells are shown.SUPERAGONIST PEPTIDE T CELL VACCINES | Chen et al. 1252
the 1G4 CTL clone stimulated by ESO 9V peptide can be ac-
counted for by a combined effect of higher peptide affinity to
A2 molecules and slower off rate of the 1G4 TCR from the
ESO 9V–A2 complex. These results are consistent with pre-
viously published data demonstrating enhanced antigen-spe-
cific antitumor immunity with altered peptide ligands (40), al-
though for the system studied by Slansky and colleagues the
effect is entirely due to a threefold slower pMHC–TCR off
rate. Although lytic granule polarization formed in response
to maximal pMHC densities has been extensively character-
ized, fewer reports have examined variations in the efficiency
of lytic granule polarization with peptide density (41). The re-
sults of our confocal microscopy experiments (Fig. 4) high-
light variations in the efficiency of lytic granule polarization
over a range of different peptide concentrations and different
stability of TCR–pMHC complexes.
Increased immunogenicity in A2 transgenic mice and
enhanced expansion of NY–ESO-1–specific CTL from mel-
anoma patients’ PBL demonstrate that the enhanced stimula-
tion of the clone 1G4 can be extended to a polyclonal popu-
lation. Although we cannot rule out the possibility that in
vivo results can mainly be accounted for by the higher affin-
ity of binding of the ESO 9V peptide to A2 molecules, it is
of interest that NY–ESO-1157–165–specific T cells from ESO
9V–primed mice have an enhanced ability to recognize tar-
get cells pulsed with the ESO 9C peptides, as compared with
NY–ESO-1157–165–specific T cells from ESO 9C primed
mice (Fig. 6 D). It is possible that this enhanced T cell activ-
ity could be due to the increased stability of the ESO 9V–A2
complex resulting in differences at the level of the immuno-
logical synapse at the T cell–DC interface and in the expan-
sion of better quality T cells. Consistent with this possibility,
differences in the molecular composition of the immunolog-
ical synapse between CTL and target cells have recently been
described at different peptide concentrations (41), resulting
in different signaling pathways and activation thresholds in
individual CTL.
It appears, therefore, that the “consensus optimization”
of the NY–ESO-1157–165 F-pocket anchor side chain to va-
line can achieve increased T cell stimulation by augmenting
the peptide affinity to A2, while maintaining, and in at least
one case enhancing TCR recognition by decreasing the dis-
sociation rate constant for TCR binding. Although the en-
hanced stability of the A2–ESO 9V variant was expected,
our combined structural and functional analysis underscores
the importance of also assessing the indirect effect of anchor
residue changes on the TCR recognition surface.
The central role of the MW peg in our complex struc-
tures is consistent with results obtained for an alanine scan of
the ESO 9C peptide using NY–ESO-1157–165–specific T cell
lines (42). A recent paper by Webb and colleagues con-
firmed the presence of this feature in the isolated A2–ESO
9C structure (43). We have extended the analysis of Webb
et al. by determining a high resolution structure (1.5 Å) of
unliganded A2 molecules loaded with the NY–ESO-1157–165
peptide analogue bearing a leucine at position 165 (A2–ESO
9L), which demonstrates that the overall structure of the
ESO 9L epitope in A2 is similar to the structure of the A2–
ESO 9V and A2–ESO 9C complexes (unpublished data). It
is of interest, however, that for isolated structures the MW
side chains are more disordered than in the TCR complexes,
consistent with the possibility that binding of the 1G4 TCR
stabilizes the MW peg. Our study has primarily focused on
TCR binding in assessing factors to be considered when en-
gineering peptide analogs. However, CD8 binding to class I
molecules is important for stabilizing the interaction be-
tween low affinity TCR and class I molecules (44) and for
controlling the dynamics of CTL activation and immuno-
logical synapse formation (45). Consistent with these find-
ings, we have shown that higher affinity recognition of the
ESO 9V peptide by the 1G4 TCR is less CD8 dependent
than recognition of the ESO 9C peptide. This alteration in
CD8 dependency does not require any change in TCR
docking orientation and therefore does not conform to the
model suggested by Buslepp and colleagues (46).
The amount of signal that T cells receive by interacting
with APCs is determined by several parameters including the
concentration of pMHC complex (class I–peptide binding
affinity) and the duration of the interaction between T cells
and APCs (TCR binding affinity). From this concept it fol-
lows that the success of vaccine strategies will be dependent
on our ability to fine tune several parameters to induce
strong T cell expansions. The use of superagonist analogs in
clinical applications provides an opportunity to address some
of the shortcomings of current vaccination strategies, as it has
been shown that peptide analogs can induce stronger re-
sponses than wild-type peptides in vivo (36–40). Peptide an-
alogs are particularly relevant in the context of recombinant
viral vector vaccination strategies, because immunodomi-
nance of viral vector–specific responses often impairs their
ability to elicit immune responses specific for recombinant
epitopes. It is possible that the low frequency of recombinant
epitope–specific CTL responses may be due to competition
from immunodominant viral epitope–specific responses, un-
derscoring the need for engineering high-affinity peptide an-
alogs for recombinant virus vaccine approaches.
In conclusion, our results highlight the indirect effects of
anchor residue substitutions on TCR binding, effects that
are of substantial significance for the rational optimization of
vaccination strategies. The sensitivity of TCR recognition
can extend to detect differences in buried anchor side chains,
resulting in altered TCR binding kinetics and different levels
of activation signals. Our results suggest the importance of
incorporating structural data into the process of identifying
candidate superagonist peptide analogs. Identification of
highly antigenic NY–ESO-1 peptide analogs is of impor-
tance for the development of vaccines capable of expanding
NY–ESO-1–specific CTL in cancer patients. Phase 1 clinical
trials using NY–ESO-1 synthetic protein, peptides and re-
combinant viruses are already in progress aimed at elicitingJEM VOL. 201, April 18, 2005 1253
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tumor-specific T cell responses. The use of the NY–ESO-1
9V analogue should be considered in future clinical trials,
because it could result in a more efficient induction of NY–
ESO-1157–165–specific CTL in cancer patients.
MATERIALS AND METHODS
pMHC production.  Residues 1–278 of the A2 heavy chain with the
COOH-terminal BirA tag were expressed in Escherichia coli as inclusion
bodies and refolded and purified with the NY–ESO-1 peptides SLLM-
WITQC or SLLMWITQV and  2 m as described previously (for example
see reference 47).
Expression and purification of the 1G4 NY–ESO-1 TCR. The 1G4
TCR was refolded and purified from E. coli derived inclusion bodies as de-
scribed in reference 6.
Crystallization and x-ray diffraction data collection.  Initial crystal-
lization screens for the 1G4 TCR (10 mg/ml), 1G4–A2-ESO 9C or 1G4–
A2-ESO 9V complexes (1:1 TCR–pMHC ratio at 10 mg/ml) used 100 nl  
100 nl drops dispensed by a Cartesian Technology Microsys MIC4000
(using Greiner 96-well protein crystallization plates), were stored in a auto-
mated vault and imaged with Veeco imaging systems. All crystallizations
were done by the sitting drop vapor diffusion technique. Crystals of the iso-
lated 1G4 TCR were grown at room temperature (21 C) from 2  l   2  l
protein   mother liquor (0.2 M sodium nitrate, 20% PEG 3350, pH 6.8) to
dimensions of 180  m   130  m   70  m. Crystals of the 1G4-A2-ESO
9C and 1G4-A2-ESO 9V complexes were grown at room temperature
(21 C) from 2  l   2  l protein   mother liquor (0.2 M potassium sodium
tartarate tetrahydrate, 20% PEG 3350, pH 7.2) to dimensions of  130
 m   80  m   70  m.
Crystals were cryoprotected in reservoir solutions containing 10 and
20% glycerol; they were then flash-cooled, and maintained at 100 K, using a
cryostream (Oxford Cryosystems). High-resolution data sets (1.4 Å for the
1G4 TCR, 1.9 Å for the 1G4–A2-ESO 9C complex and 1.7 Å for the
1G4–A2-ESO 9V complex) were collected at station ID14 EH2 of the Eu-
ropean Synchrotron Radiation Facility (ESRF, Grenoble, France) with an
Area Detector Systems Corporation Quantum 4 CCD detector. The 1G4–
A2-ESO 9C and the 1G4–A2–ESO 9V complex crystals belonged to space
group P21. Data were auto-indexed and integrated with the program
DENZO (48), and scaled with the program SCALEPACK (48; Table I).
Crystal structure determination, refinement, and analysis.  The
structures of the 1G4 TCR, 1G4–A2-ESO 9C, and the 1G4–A2-ESO 9V
complexes were determined by molecular replacement with the program
EPMR (49). For the two pMHC–TCR complexes, initial solutions were ob-
tained for the HLA-A2 heavy chain, and  2M followed by a second round of
molecular replacement with the A6 TCR used as a search probe while the A2
solution was kept fixed. The 1G4 molecular replacement was solved with the
A6 TCR in a single round of molecular replacement. The program SWISS-
MODEL (www.expasy.org/swissmod/SWISS-MODEL.html) was used to
replace the A6 TCR sequence with that of 1G4 before refinement.
Using CNS (50), the models were refined as rigid body domains ( 1
and  2,  3,  2M, peptide, V , V , C , and C  for the complexes and the
V , V , C , and C  TCR domains for the 1G4 data). Subsequent minimi-
zation procedures included positional refinement, simulated annealing and
restrained individual B factor refinement with bulk solvent correction and
overall anisotropic B factor scaling. Manual refitting of the models was done
with the interactive graphics program O (51), and water molecules were
added at the last stages of refinement on the basis of peaks that were at least
3.0  in height in Fobs – Fcalc electron density maps. The CDR loops of the
isolated TCR showed significantly higher B factors than when complexed
with pMHC, but the electron density was of sufficient quality to allow posi-
tioning of a single dominant main chain conformation for all of these loops.
We assessed the stereochemistry of the refined structures with the
program PROCHECK (52). Surface complementarity calculations were
done with the CCP4 program Sc (53; probe size 1.7 Å). To allow com-
parison of similar Sc values between structures it was necessary to estimate
the standard uncertainty in atomic positions in the structures and how this
translates to uncertainty in Sc value. For the 1G4–A2-ESO 9C complex
(the lowest resolution structure) the standard uncertainty in atomic posi-
tions derived by Refmac (54) using the Rfree was 0.148 Å. By running Sc
100 times on an ensemble of structures for this complex with the x, y, and
z coordinates of each atom randomly perturbed using a Gaussian distribu-
tion of standard deviation 0.148 Å, we estimate the standard uncertainty in
Sc to be 0.017. Thus, although the difference in Sc values for the two
complexes is small, we believe it to be significant. Solvent accessibility cal-
culations were done with Naccess (http://wolf.bms.umist.ac.uk/naccess/;
probe size 1.4 Å). Graphical representations of the structure were prepared
using programs Bobscript (55) and CSC Chemdraw (Cambridge Scientific
Computing, Inc.).
Surface plasmon resonance. Surface plasmon resonance experiments
were performed by using a Biacore3000 (Biacore). Biotinylated soluble
HLA (ligand) was immobilized on Streptavidin-coated CM5 chip (Biacore)
at the level of 1,000 RU (response units) per flow cell. Equilibrium binding
was measured at the flow rate of 5  l/min, starting from the lowest analyte
concentration. The data points were plotted using Origin software. Kd val-
ues were calculated using the standard hyperbolic model fitting kinetics ex-
periments. Kinetics of TCR–pMHC interactions was measured at 30  l/
min. The curves were then fitted using a simultaneous kon/koff fitting model
(Bioevaluation software; Biacore).
MHC class I assembly assay. This assay was performed as previously
described (31).
Flow cytometry. 3   104 T2 cells were pulsed with different concentra-
tions of peptides for 2 h at 37 C. Cells were incubated with 40  g/ml bio-
tinylated Fab antibodies for 30 min at 4 C and visualized by Streptavidin-
conjugated R-PE (Sigma-Aldrich) for 20 min at room temperature.
Confocal microscopy analysis. T2 target cells were pulsed with 1  M,
100 nM, 10 nM, 5 nM, and 1 nM of either ESO 9C or ESO 9V peptide for
1 h at 37 C and washed twice in PBS. 1G4 CTL and T2 cells were washed
in PBS and each cell pellet was resuspended to a final concentration of 5  
105 cells/ml in RPMI. 1G4 CTL and target were mixed 1:1, left for 5 min
in suspension, and the plated on glass multiwell slides and incubated for 30
min at 37 C. Cells were fixed in 100% methanol precooled to  20 C,
washed in PBS, and blocked in PBS, 2% BSA (Sigma-Aldrich). The slides
were mounted in PBS containing 90% glycerol and 2.5% DABCO. Samples
were examined using a Bio-Rad Radiance 2000 MP laser scanning micro-
scope and the conjugation rate and granule polarization were quantified us-
ing an Axioplan 2 epifluorescent microscope (Zeiss).
Live cell video microscopy. 2   104 1G4 CTL were incubated with 60 nM
lysotracker green DND-26 (Molecular Probes) for 1 h at 37 C in RPMI, 5%
human serum, and washed once in PBS and resuspended in 100 ml RPMI
without phenol red, 5% human serum, 1 mM Hepes. T2 target cells were pulsed
with 1  M of either ESO 9C peptide or ESO 9V peptide for 1 h at 37 C
and washed twice in PBS. 2   104 target cells were allowed to adhere on a
glass coverslip mounted in a temperature-controlled chamber for 10 min at
37 C in RPMI without serum, without phenol red plus Hepes. Lysotracker
green DND-26–labeled 1G4 NY–ESO-1157–165 CTL were added to the T2
cells in the chamber. Sequential confocal images were acquired every 20 s.
CD8-independent ELISA assays for soluble cytokines. 1G4 CTL
and pulsed B cell targets were incubated at 37 C for 4 h at an effector–target
ratio of 1:1. After 4 h the supernatant was harvested and assayed for MIP-1 
and IFN-  by ELISA (R&D Systems). Standard deviation from the mean of
two duplicate assays is shown.SUPERAGONIST PEPTIDE T CELL VACCINES | Chen et al. 1254
Vaccination of A2Kb mice and ex vivo tetramer staining. A2Kb
transgenic mice were vaccinated using a DNA-prime/recombinant vaccinia
virus–boost strategy (56). Mice were injected intramuscularly with 50  g
plasmid DNA encoding either ESO 9V or ESO 9C peptide followed by in-
travenous injection with 5   106 plaque forming units recombinant vac-
cinia virus containing the same antigens on day 10. 10 d after injection,
fresh PBL were isolated from blood taken from the tail vein using red cell
lysis buffer (Invitrogen). A2Kb tetramer for ex vivo staining were synthe-
sized as previously described (57). Approval of care and use of animals was
obtained from the Clinical Medicine Ethical Review Committee (Univer-
sity of Oxford, Oxford, UK) and by the UK Home Office.
Ex-vivo IFN-  ELISPOT assay. ELISPOT analysis for mouse IFN- 
secretion was performed with cells incubated overnight according to the
protocol provided by the manufacturer (Mabtech). Mice splenocytes were
generated using the method described above and rested in RPMI supple-
mented with 10% FCS at 4 C overnight.
In the experiment shown in Fig. 6 D, ESO 9C peptide was treated
with 20 mM TCEP at room temperature for 1 h before being added to the
wells at the final concentration of 200  M.
Accession numbers. Atomic coordinates and structure factor amplitudes
for the 1G4 TCR–ESO 9C–A2 complex, 1G4 TCR–ESO 9V–A2 com-
plex, and the 1G4 TCR have been deposited in the Protein Data Bank un-
der accession numbers 2BNR, 2BNQ, and 2BNU, respectively.
Online supplemental materials. For surface plasmon resonance, the an-
tibody binding assay shown in Fig. S1, 10 serial dilutions in duplicates of
BB7.2 and BBM.1 were made. For live cell video microscopy (Videos 1
and 2) a Nikon TE300 microscope attached to a Bio-Rad Radiance 200
MP laser scanning microscope was used with a 488-nm laser for epifluores-
cence and Nomarski differential interference contrast for transmitted light.
The images were processed using MetaMorph version 4.5 software. Online
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20042323/DC1.
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